市場調査レポート

世界の個別化診断(オーダーメイド診断)市場

World Market for Personalized Medicine Diagnostics (Biomarkers, Pharmacodiagnostics, Tumor Assays, Cardiac Risk and Other Testing)

発行 Kalorama Information 商品コード 231620
出版日 ページ情報 英文 430 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.12円で換算しております。
Back to Top
世界の個別化診断(オーダーメイド診断)市場 World Market for Personalized Medicine Diagnostics (Biomarkers, Pharmacodiagnostics, Tumor Assays, Cardiac Risk and Other Testing)
出版日: 2012年03月01日 ページ情報: 英文 430 Pages
概要

当レポートでは、臨床検査における個別化診断(オーダーメイド診断)の市場機会と将来的な潜在性について調査分析し、個別化診断の発展の経緯と直面している制約・課題、疾患標的、現行および開発中の検査・バイオマーカー・診断技術の各種動向、主要国/地域における動向、主要事業者の取り組み、戦略的提言などをまとめ、概略以下の構成でお届けいたします。

第1章 エグゼクティブサマリー

  • イントロダクション
  • 調査範囲・調査手法
  • 市場規模・成長率
  • 市場動向

第2章 イントロダクション

  • 背景
  • 2000年以降の発展:個別化医療の制約と将来の展望
  • リスクと治療の個別化
  • 個別化治療薬:薬剤・ワクチン・その他
  • 個別化医療の各種側面

第3章 戦略的課題:「COMMERCIALIZATION CONDUNDRUM(商業化という難問)」

  • 背景
  • 新しい検査の償還
  • 医療費支払い者の展望と方針
  • 法規制上の課題と個別化アッセイ
  • IVDかCLIAか、あるいは両方か
  • 医師への教育と医師による受容
  • 特許上の課題と個別化診断の商業化
  • POC検査の展望

第4章 疾患標的

  • 背景
  • バイオマーカーのバリデーションと有用性
  • シトクロムP450と薬物代謝
  • 乳癌におけるエステロゲン受容体とプロゲステロン受容体
  • HER2過剰発現とハーセプチン・タイケルブ
  • 上皮成長因子受容体(EGFR:Epidermal Growth Factor Receptor)
  • 大腸がんのKRAS変異と抗EGFR薬
  • BRAF変位と癌治療薬
  • UGT1A1遺伝子多型
  • フルオロウラシル(5−FU)治療薬
  • PIK3CA遺伝子多型
  • KIF6遺伝子多型
  • ALK遺伝子多型

第5章 診断技術

  • PCRベースのアッセイ
  • 一塩基多型(SNP:Single Nucleotide Polymorphism)の遺伝子型タイピング
  • 次世代シーケンシング
  • LDTの支配
  • 小型化・複合化アッセイ
  • 癌領域における複数の遺伝子/バイオマーカーによる試験
  • マススペクトロスコピー
  • ナノバイオテクノロジーの役割
  • プロテオミクスとバイオマーカーの検出
  • 分子イメージングと個別化医療
  • 情報技術

第6章 市場分析

  • 背景
  • 個別化診断の世界における市場機会
    • 米国
    • 欧州
    • 日本
    • その他
  • 医薬品および診断関連事業者間の契約
  • IVD関連事業者およびCLIAラボ間の契約
  • 主要企業およびラボ
  • 癌の管理における個別化医療の市場
    • 細胞組織ベースの検査
    • 血液マーカー
    • 循環腫瘍細胞
  • 感染症における個別化医療の市場
    • HIV
    • HBV
    • HCV
    • 院内感染症
  • 凝固療法における個別化医療の市場
    • ワルファリン
    • 血小板機能
  • 自己免疫疾患における個別化医療の市場
  • 心血管系疾病における個別化医療の市場
  • CNS障害における個別化医療の市場
  • 糖尿病における個別化医療の市場
  • 輸血安全性部門における個別化医療の市場
  • 健康・美容部門における個別化医療の市場

第7章 総論・戦略的提言

第8章 企業プロファイル

図表

目次
Product Code: KLI6640829

In this market research report, Kalorama Information defines the current opportunity and a realistic future potential for personalized medicine in clinical testing. In addition to looking at tests on the market currently, the report profiles key competitors and discusses trends important for understanding this much-discussed growth area for the diagnostic industry.

The concept of ‘Personalized Medicine’ currently, as seen by Kalorama clinical diagnostics industry analyst Shara Rosen, is somewhere between dream and road to reality. Fantastic promises have been made over the years in the press and reports of startup concerns. But slowly and surely, real revenues are appearing, and realistic models for future growth will be seen. Developments that are linked in the press to 'personalized medicine' are many and can at times be confusing. But there are several discovered biomarkers that are significant in diagnostic markets. Biomarkers discussed in the report include:

  • Cytochrome P450 and Drug Metabolism
  • Estrogen Receptor and Progesterone
  • Receptor Status for Breast Cancer
  • HER2 Overexpression and Herceptin and Tykerb
  • Epidermal Growth Factor Receptor (EGFR)
  • KRAS Mutations and Anti-EGFR Therapy for Colorectal Cancer
  • BRAF Mutations and Cancer Therapy
  • UGT1A1 Genetic Variants
  • 5-Flurouracil Therapy
  • PIK3CA Genetic Variation
  • KIF6 Genetic Variation
  • ALK Genetic Variation

This is a highly active market. A special focus of the report is the amount of collaborations between IVD and pharmaceutical companies, as well as IVD companies and CLIA labs. This report will profile scores of such companies operating in this market and estimate and forecast markets for personalized medicine technologies in the following categories:

  • World Market for Personalized Medicine Diagnostics by Disease (Cardiovascular, Nutritional Conditions, Diabetes, CNS,
  • Blood Transfusion)
  • World Market for Tissue-based Tests Personalized Medicine Diagnostics
  • World Market for Blood Markers Personalized Medicine Diagnostics
  • World Market for Circulating Tumor Cells Personalized Medicine Diagnostics
  • World Market for HIV Personalized Medicine Diagnostics
  • World Market for HBV Personalized Medicine Diagnostics
  • World Market for HCV Personalized Medicine Diagnostics
  • World Market for Hospital Acquired Infection Personalized Medicine Diagnostics
  • World Market for Warfarin Personalized Medicine Diagnostics
  • World Market for Platelet Function Personalized Medicine Diagnostics

Companies profiled in this report include:

The Major IVD Companies

  • Abbott Diagnostics Beckman Coulter Inc.
  • Becton,
  • Dickinson and Company
  • bioMerieux Inc.
  • Celera Corporation
  • Cepheid
  • China Medical Technologies
  • Dako Denmark A/S
  • Fujirebio Diagnostics, Inc.
  • GE Healthcare
  • Gen-Probe Inc.
  • Immucor, Inc.
  • Luminex Corporation
  • PerkinElmer Inc.
  • Phadia AB
  • QIAGEN N.V.
  • Roche Diagnostics
  • Siemens Healthcare Diagnostics
  • Ventana Medical Systems Inc.
  • Wako Diagnostics

Participants

  • 20/20 GeneSystems, Inc.
  • 23andMe
  • Accumetrics
  • AdvanDx, Inc.
  • Affymetrix, Inc.
  • Agendia BV
  • Almac Diagnostics
  • AltheaDx, Inc.
  • Ambry Genetics
  • Arrayit Corporation
  • ARUP Laboratories
  • AssureRx Health, Inc.
  • Asuragen, Inc.
  • Autogenomics Inc.
  • BG Medicine, Inc.
  • Biocare Medical, LLC
  • Biocartis SA
  • Biocept, Inc.
  • BioCurex, Inc.
  • Biodesix, Inc.
  • BioReference Laboratories, Inc.
  • BioServe
  • bioTheranostics
  • Clarient Inc.
  • CombiMatrix Molecular Diagnostics, Inc.
  • Corgenix Medical Corporation
  • Cylex, Inc.
  • Dana Farber Cancer Institute
  • DeCode Genetics
  • DxS Ltd.
  • DxTerity Diagnostics Inc.
  • Enzo Clinical Labs
  • Epigenomics AG
  • Euroimmun AG
  • Genelex Corporation
  • Genomic Health, Inc.
  • Genoptix Medical Laboratory
  • Genzyme Genetics
  • Illumina Inc.
  • Interleukin Genetics, Inc.
  • Ipsogen SA
  • Knome, Inc.
  • Lab21 Limited
  • Laboratory Corporation of America Holdings
  • LabCorp)
  • Life Technologies Corporation
  • Mayo Medical Laboratories
  • MDxHealth SA
  • Monogram Biosciences, Inc.
  • Myriad Genetics, Inc.
  • Nanosphere, Inc.
  • Navigenics
  • Pathway Genomics
  • Pathwork Diagnostics, Inc.
  • Power3 Medical Products, Inc.
  • Precision Therapeutics
  • Predictive Biosciences
  • Progenika Inc.
  • Prometheus Laboratories Inc.
  • Quest Diagnostics Incorporated
  • Response Genetics, Inc.
  • Rosetta Genomics
  • Rules-Based Medicine, Inc.
  • Saladax Biomedical, Inc.
  • Sequenom, Inc.
  • TGen (The Translational Genomics
  • Research Institute)
  • TrimGen Corporation
  • TrovaGene, Inc.
  • Veridex, LLC
  • Vermillion Inc.
  • Virco BVBA
  • XDx, Inc.

The Newcomers

  • Abkine Pharmaceuticals
  • Accelerated Medical Diagnostics, LLC
  • Advanced Biological Laboratories
  • Affomix Corporation
  • Ahram Biosystems, Inc.
  • Alacris Theranostics GmbH
  • Amoy Diagnostics Co. Ltd.
  • ApoCell, Inc.
  • Atossa Genetics, Inc.
  • Augurex Life Sciences Corp.
  • Biofortuna Ltd.
  • Biomarker Factory, The
  • BioMarker Strategies
  • Biomedical Diagnostics
  • BlackBio S.L.
  • Bostwick Laboratories
  • Cancer Genetics, Inc.
  • Cancer Treatment Centers of America
  • CancerGuide Diagnostics, Inc.
  • CardioDx, Inc.
  • Caris Life Sciences
  • Chronix Biomedical
  • Crescendo Bioscience, Inc.
  • Critical Diagnostics
  • Curidium Medica Limited
  • CvergenX
  • DermaGenoma, Inc.
  • DiaTech Oncology
  • Eutropics Pharmaceuticals
  • Everist Genomics
  • Evotec AG
  • Exosome Diagnostics Inc.
  • Foundation Medicine Inc.
  • GeneNews Limited
  • Genetic Technologies Limited
  • GenMark Diagnostics Inc.
  • Genomas
  • Genomind, LLC
  • GenoVive LLC
  • GMS Biotech
  • Inostics GmbH
  • Insight Genetics
  • IntegraGen SA
  • IRIS International, Inc.
  • Iverson Genetic Diagnostics, Inc.
  • Linkage Biosciences, Inc.
  • Med BioGene, Inc.
  • Medco Health Solutions Inc.
  • Metamark Genetics, Inc.
  • Mira Dx
  • Molecular Response
  • MolecularMD Corp.
  • Nanostring Technologies, Inc.
  • NaturalNano, Inc.
  • NewGene
  • NobleGen Biosciences
  • Nodality Inc.
  • Novartis Molecular Diagnostics
  • Nuvera Biosciences, Inc.
  • On-Q-ity
  • Orion Genomics
  • OvaGene Oncology, Inc.
  • Pacific Edge Biotechnology Limited
  • Pathogenica
  • Pharmigene
  • Pinpoint Genomics, Inc.
  • Population Diagnostics, Inc.
  • Proctor & Gamble
  • Psynomics Incorporated
  • Radient Pharmaceuticals Corporation
  • ScreenCell
  • Scripps Health
  • Seegene Inc.
  • Signal Genetics
  • Signature Diagnostics AG
  • Sirius Genomics
  • Skyline Diagnostics B.V.
  • Spartan Bioscience Inc.
  • SureGene, LLC
  • TcLand Expression SA
  • Transgenomic, Inc.
  • ViennaLab Diagnostics GmbH

Information Technology Specialists

  • CLC bio
  • CollabRx
  • Definiens
  • Dell Healthcare and Life Sciences
  • DNA Direct
  • GenomeQuest Inc.
  • HolGenTech Inc.
  • IDBS
  • MediSapiens Ltd.
  • Partners HealthCare Center for Personalized
  • Genetic Medicine
  • Selventa
  • Sophic Systems Alliance

Table of Contents

CHAPTER ONE: EXECUTIVE SUMMARY

  • Introduction
  • Scope and Methodology
  • Size and Growth of the Market
  • Market Trends

CHAPTER TWO: INTRODUCTION

  • Background
  • Developments since 2000 - Limitations of Personalized Medicine and Future Prospects
  • Personalizing risk and therapies
  • Personalized Therapies - drugs, vaccines and others
  • Aspects of Personalized Medicine
    • Screening for Disease Risk
    • Early diagnosis
    • Therapy Selection and Monitoring

CHAPTER THREE: STRATEGIC ISSUES: THE “COMMERCIALIZATION CONDUNDRUM”

  • Background
  • Reimbursement of Novel Tests
    • United States
    • Europe
  • Payor Perspectives and Policies
  • Regulatory Issues and Personalized Medicine Assays
    • United States
    • Europe
  • IVD vs CLIA or Both
  • Physician Education and Acceptance
  • Patent Issues and Commercializing Personalized Diagnostics
  • Prospects for POC Testing

CHAPTER FOUR: DISEASE TARGETS

  • Background
  • Biomarker Validation and Utility
  • Cytochrome P450 and Drug Metabolism
  • Estrogen Receptor and Progesterone Receptor Status for Breast Cancer
  • HER2 Overexpression and Herceptin and Tykerb
  • Epidermal Growth Factor Receptor (EGFR)
  • KRAS Mutations and Anti-EGFR Therapy for Colorectal Cancer
  • BRAF Mutations and Cancer Therapy
  • UGT1A1 Genetic Variants
  • 5-Flurouracil Therapy
  • PIK3CA Genetic Variation
  • KIF6 Genetic Variation
  • ALK Genetic Variation

CHAPTER FIVE: DIAGNOSTIC TECHNOLOGIES

  • PCR-based assays
  • Single nucleotide polymorphism (SNP) genotyping
  • Next-gen sequencing
  • LDTs reign
  • Miniaturization and Multiplexed Assays
  • Multi-Gene/Biomarker Tests in Oncology
  • Mass Spectroscopy
  • Role of Nanobiotechnology
  • Proteomics and Biomarker Detection
  • Molecular Imaging and Personalized Medicine
  • Information Technology

CHAPTER SIX: MARKET ANALYSIS

  • Background
  • Worldwide Opportunities for Personalized Medicine Diagnostics
    • The United States
    • Europe
    • Japan
    • ROW
  • Agreements between Pharmaceutical and Diagnostic Companies
  • Agreements between IVD companies and CLIA labs
  • Major Companies and Labs
  • The Market for Personalized Medicine in Cancer Management
    • Tissue-based Tests
    • Blood Markers
    • Circulating Tumor Cells
  • The Market for Personalized Medicine in Infectious Diseases
    • HIV
    • HBV
    • HCV
    • Hospital Acquired Infections
  • The Market for Personalized Medicine in Coagulation Therapy
    • Warfarin
    • Platelet Function
  • The Market for Personalized Medicine in Autoimmune Diseases
  • The Market for Personalized Medicine in Cardiovascular Diseases
  • The Market for Personalized Medicine in CNS Disorders
  • The Market for Personalized Medicine in Diabetes
  • The Market for Personalized Medicine in Blood Transfusion Safety
  • The Market for Personalized Medicine in Nutrition and Beauty

CHAPTER SEVEN: CONCLUSIONS AND STRATEGIC IMPLICATIONS

CHAPTER EIGHT: COMPANY PROFILES

The Major IVD Companies

  • Abbott Diagnostics Beckman Coulter Inc. Becton,
  • Dickinson and Company
  • bioMérieux Inc.
  • Celera Corporation
  • Cepheid
  • China Medical Technologies
  • Dako Denmark A/S
  • Fujirebio Diagnostics, Inc.
  • GE Healthcare
  • Gen-Probe Inc.
  • Immucor, Inc.
  • Luminex Corporation
  • PerkinElmer Inc.
  • Phadia AB
  • QIAGEN N.V.
  • Roche Diagnostics
  • Siemens Healthcare Diagnostics
  • Ventana Medical Systems Inc.
  • Wako Diagnostics

Participants

  • 20/20 GeneSystems, Inc.
  • 23andMe
  • Accumetrics
  • AdvanDx, Inc.
  • Affymetrix, Inc.
  • Agendia BV
  • Almac Diagnostics
  • AltheaDx, Inc.
  • Ambry Genetics
  • Arrayit Corporation
  • ARUP Laboratories
  • AssureRx Health, Inc.
  • Asuragen, Inc.
  • Autogenomics Inc.
  • BG Medicine, Inc.
  • Biocare Medical, LLC
  • Biocartis SA
  • Biocept, Inc.
  • BioCurex, Inc.
  • Biodesix, Inc.
  • BioReference Laboratories, Inc.
  • BioServe
  • bioTheranostics
  • Clarient Inc.
  • CombiMatrix Molecular Diagnostics, Inc.
  • Corgenix Medical Corporation
  • Cylex, Inc.
  • Dana Farber Cancer Institute
  • DeCode Genetics
  • DxS Ltd.
  • DxTerity Diagnostics Inc.
  • Enzo Clinical Labs
  • Epigenomics AG
  • Euroimmun AG
  • Genelex Corporation
  • Genomic Health, Inc.
  • Genoptix Medical Laboratory
  • Genzyme Genetics
  • Illumina Inc.
  • Interleukin Genetics, Inc.
  • Ipsogen SA
  • Knome, Inc.
  • Lab21 Limited
  • Laboratory Corporation of America Holdings (LabCorp)
  • Life Technologies Corporation
  • Mayo Medical Laboratories
  • MDxHealth SA
  • Monogram Biosciences, Inc.
  • Myriad Genetics, Inc.
  • Nanosphere, Inc.
  • Navigenics
  • Pathway Genomics
  • Pathwork Diagnostics, Inc.
  • Power3 Medical Products, Inc.
  • Precision Therapeutics
  • Predictive Biosciences
  • Progenika Inc.
  • Prometheus Laboratories Inc.
  • Quest Diagnostics Incorporated
  • Response Genetics, Inc.
  • Rosetta Genomics
  • Rules-Based Medicine, Inc.
  • Saladax Biomedical, Inc.
  • Sequenom, Inc.
  • TGen (The Translational Genomics Research Institute)
  • TrimGen Corporation
  • TrovaGene, Inc.
  • Veridex, LLC
  • Vermillion Inc.
  • Virco BVBA
  • XDx, Inc.

The Newcomers

  • Abkine Pharmaceuticals
  • Accelerated Medical Diagnostics, LLC
  • Advanced Biological Laboratories
  • Affomix Corporation
  • Ahram Biosystems, Inc.
  • Alacris Theranostics GmbH
  • Amoy Diagnostics Co. Ltd.
  • ApoCell, Inc.
  • Atossa Genetics, Inc.
  • Augurex Life Sciences Corp.
  • Biofortuna Ltd.
  • Biomarker Factory, The
  • BioMarker Strategies
  • Biomedical Diagnostics
  • BlackBio S.L.
  • Bostwick Laboratories
  • Cancer Genetics, Inc.
  • Cancer Treatment Centers of America
  • CancerGuide Diagnostics, Inc.
  • CardioDx, Inc.
  • Caris Life Sciences
  • Chronix Biomedical
  • Crescendo Bioscience, Inc.
  • Critical Diagnostics
  • Curidium Medica Limited
  • CvergenX
  • DermaGenoma, Inc.
  • DiaTech Oncology
  • Eutropics Pharmaceuticals
  • Everist Genomics
  • Evotec AG
  • Exosome Diagnostics Inc.
  • Foundation Medicine Inc.
  • GeneNews Limited
  • Genetic Technologies Limited
  • GenMark Diagnostics Inc.
  • Genomas
  • Genomind, LLC
  • GenoVive LLC
  • GMS Biotech
  • Inostics GmbH
  • Insight Genetics
  • IntegraGen SA
  • IRIS International, Inc.
  • Iverson Genetic Diagnostics, Inc.
  • Linkage Biosciences, Inc.
  • Med BioGene, Inc.
  • Medco Health Solutions Inc.
  • Metamark Genetics, Inc.
  • Mira Dx
  • Molecular Response
  • MolecularMD Corp.
  • Nanostring Technologies, Inc.
  • NaturalNano, Inc.
  • NewGene
  • NobleGen Biosciences
  • Nodality Inc.
  • Novartis Molecular Diagnostics
  • Nuvera Biosciences, Inc.
  • On-Q-ity
  • Orion Genomics
  • OvaGene Oncology, Inc.
  • Pacific Edge Biotechnology Limited
  • Pathogenica
  • Pharmigene
  • Pinpoint Genomics, Inc.
  • Population Diagnostics, Inc.
  • Proctor & Gamble
  • Psynomics Incorporated
  • Radient Pharmaceuticals Corporation
  • ScreenCell
  • Scripps Health
  • Seegene Inc.
  • Signal Genetics
  • Signature Diagnostics AG
  • Sirius Genomics
  • Skyline Diagnostics B.V.
  • Spartan Bioscience Inc.
  • SureGene, LLC
  • TcLand Expression SA
  • Transgenomic, Inc.
  • ViennaLab Diagnostics GmbH

Information Technology Specialists

  • CLC bio
  • CollabRx
  • Definiens
  • Dell Healthcare and Life Sciences
  • DNA Direct
  • GenomeQuest Inc.
  • HolGenTech Inc.
  • IDBS
  • MediSapiens Ltd.
  • Partners HealthCare Center for Personalized Genetic Medicine
  • Selventa
  • Sophic Systems Alliance

LIST OF TABLES

CHAPTER ONE: EXECUTIVE SUMMARY

  • Table 1-1. Exchange Rate Fluctuations, 2005-2010
  • Table 1-2. Worldwide Personalized Medicine Test Sales, 2011-2016

CHAPTER THREE: STRATEGIC ISSUES: THE “COMMERCIALIZATION CONDUNDRUM”

  • Table 3-1. Selected Company Sponsored Certified Labs
  • Table 3-2. Proposed Palmetto non-coverage tests
  • Table 3-3. Selected LDT Companies Cited by the FDA
  • Table 3-4. Selected POC-appropriate Systems

CHAPTER FOUR: DISEASE TARGETS

  • Table 4-1. Selected Drug/Biomarker Targets in the U.S.
  • Table 4-2. Selected drugs that require PMx testing in Europe
  • Table 4-3. Selected Commercial CYP450 Warfarin Tests
  • Table 4-4. Selected drugs associated with CYP450 metabolism
  • Table 4-5. Selected innovations in EFGR tests
  • Table 4-6. Selected KRAS test innovations
  • Table 4-7. Selected BRAF gene test innovations
  • Table 4-8. Selected PIK3CA mutation test innovations
  • Table 4-9. Selected Innovations in CTC Systems
  • Table 4-10. Selected Live Cell Assays

CHAPTER FIVE: DIAGNOSTIC TECHNOLOGIES

  • Table 5-1. Selected Novel Nucleic Acid Testing Platforms, 2008-2011
  • Table 5-2. Major Sequencing Platforms
  • Table 5-3. Selected innovations in sequencing
  • Table 5-4. Selected Company Sponsored Certified Labs
  • Table 5-5. Selected LDT Service Provider Revenues, 2007-2011
  • Table 5-6. Selected PMx tests using microarrays
  • Table 5-7. Selected Gene Expression Tests
  • Table 5-8. Selected innovations in mass spectroscopy for personalized medicine
  • Table 5-9. Selected novel biomarkers under investigation
  • Table 5-10. Selected Innovations in Protein Biomarkers
  • Table 5-11. Selected companies involved in chromosomal analysis of cells
  • Table 5-12. Selected test digital platform innovations
  • Table 5-13. Selected blood-based tests in personalized medicine
  • Table 5-14. IT solutions for personalized medicine

CHAPTER SIX: MARKET ANALYSIS

  • Table 6-1. Worldwide Commercial Personalized Medicine Test Sales, by category
  • Table 6-2. Market Penetration Of PMx Tests, by geographic area, 2011-2016
  • Table 6-3. Selected Agreements between IVD Companies and Lab Services
  • Table 6-4. Worldwide Sales of PMx Tests for Cancer, by category, 2011-2016
  • Table 6-5. Major protein and molecular markers used in tissue staining
  • Table 6-6. Selected Pharmacodiagnostic Histology Tests
  • Table 6-7. Selected chromosome-based cancer tests and services
  • Table 6-8. Selected HPV tests
  • Table 6-9. Selected Tumor Marker Innovations, 2008-2011
  • Table 6-10. Selected Innovations in Molecular PMx Tests for Cancer
  • Table 6-11. PMx Test Sales for Infectious Diseases, worldwide, 2011-2016
  • Table 6-12. Selected PMx tests for infectious diseases
  • Table 6-13. Selected commercial MDR-TB test kits
  • Table 6-14. Selected molecular PMx coagulation tests
  • Table 6-15. Selected innovations in PMx testing for autoimmune diseases
  • Table 6-16. Selected IVD markers of CVD
  • Table 6-17. Worldwide PMx product sales for CVD, by category, 2011-2016
  • Table 6-18. Selected Cardiac Marker Innovations, 2008-2011
  • Table 6-19. Selected innovations in genetic tests for CVD
  • Table 6-20. Selected innovations in personalized tests for CNS diseases
Back to Top